Aflac AFL Cancer — Liability for Future Policy Benefit, after Reinsurance

Other product segments

Similar metrics at other companies

HMNCancer — Liability for Future Policy Benefit, after Reinsurance

$64.4M-10.7%

EQHHealth — Liability for Future Policy Benefit, after Reinsurance

$283M-3.4%

HMNOther — Liability for Future Policy Benefit, after Reinsurance

$80.3M-6.7%

GELong-term care — Liability for Future Policy Benefit, after Reinsurance

$24.79B+1.0%

GLHealth — Liability for Future Policy Benefit, after Reinsurance

$2.43B+2.9%

GLLife — Liability for Future Policy Benefit, after Reinsurance

$15.02B+1.2%

Questions, answered.

What is Aflac's cancer — liability for future policy benefit, after reinsurance?

Aflac (AFL) reported cancer — liability for future policy benefit, after reinsurance of $17.28B in Q1 2026.

How has Aflac's cancer — liability for future policy benefit, after reinsurance changed year-over-year?

Aflac's cancer — liability for future policy benefit, after reinsurance decreased by 20.7% year-over-year, from $21.79B to $17.28B.

What is the long-term trend for Aflac's cancer — liability for future policy benefit, after reinsurance?

Over 2 years (2023 to 2025), Aflac's cancer — liability for future policy benefit, after reinsurance has grown at a -14.5% compound annual growth rate (CAGR), from $112.45B to $82.11B.

What does cancer — liability for future policy benefit, after reinsurance mean?

This represents the actuarial estimate of the present value of future benefits payable to policyholders in the cancer insurance segment, net of any reinsurance recoveries. It reflects the long-term financial obligation the company must hold to cover future claims for this specific product line. This metric is critical for assessing the long-term solvency and reserve adequacy of the cancer insurance business.